← Astria Therapeutics, Inc. (ATXS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Astria Therapeutics, Inc. (ATXS)
Pharmaceutical Preparations · market cap $718M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 3
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Astria Therapeutics (ATXS) is a clinical-stage pharmaceutical company with 78 employees and a ~$718M market cap focused on rare disease, specifically Hereditary Angioedema (HAE). Its lead asset, navenibart, is in Phase 3, with a key readout expected around December 2026. A second HAE asset, STAR-0215, is in Phase 2, making the company a single-indication, two-asset story at this stage.
The catalyst path
- 2026-12-15 (est.)Phase 3 · navenibartimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| navenibart | Phase 3 | Hereditary Angioedema (HAE) |
| STAR-0215 | Phase 2 | Hereditary Angioedema |
Price & technical context
3-month
+3.0%
6-month
+91.8%
12-month
+67.7%
52-wk range
$3.75–$13.20
vs 50-day MA
-1.3%
vs 200-day MA
+51.2%
Realized vol
70.0%
Max drawdown
-77.5%
Daily closes through 2026-01-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ATXS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.